NR3C2 and Hypertension: Indeed, numerous experimental and clinical evidences indicate that pharmacological inhibition of RAAS with angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), direct rennin inhibitors (DRIs), and mineralocorticoid receptor antagonists (MRAs) is effective in treating hypertension and diabetic renal injury, and the results show a reduction in CVD and heart-related events worldwide [1].